Navigation Links
German federal government bolsters neutron research in Garching
Date:12/17/2010

the responsible operator, and the three Helmholz Centers," says TUM President Professor Wolfgang A. Hermann. "The foundation for this cooperation is the unrivaled performance spectrum of our neutron source, which attracts researchers from across the globe. A joint chair with the Forschungszentrum Juelich in the field of neutron research would round things off perfectly."

Pursuant to this agreement, the TU Muenchen and the three Helmholtz Centers will operate the FRM II jointly for scientific uses in the future. The Technische Universitaet Muenchen remains the sole operator of the neutron source itself. That is why the State of Bavaria will continue to fund reactor operation and research with 25 million euros annually.

FRM II Scientific Director Professor Winfried Petry is proud of the awarded grant: "The involvement of the Helmholtz Centers and the BMBF is the best evidence that we are already performing exceptionally well. The FRM II provides researchers with neutron beams of the utmost brilliance and its instruments lead the pack. This grant will provide us with the opportunity to exploit the potential of the neutron source even better in supporting top level German and international research."

Concretely, the grant will be used to build new instruments, to upgrade existing instruments, and to increase technical and scientific staff. New office and laboratory space will also need to be created for the additional personnel. Currently, 24 instruments at the FRM II are already at the disposal of guest scientists from around the world. The number of large-scale instruments will rise to over 30 in the near future. Measurement slots at the FRM II are in high demand. They are overbooked at more than twice the available capacity and are awarded via an application system based on scientific excellence and run by independent experts.

The cooperation contract is an extension to a cooperation agreement from 2004 with the FZ Juelich
'/>"/>

Contact: Patrick Regan
regan@zv.tum.de
49-892-891-0515
Technische Universitaet Muenchen
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. SEBM European Best Poster Prize awarded at Annual Conference of the German Society for Gene Therapy
2. German-Russian Otto Schmidt Laboratory in St. Petersburg funded for another 3 years
3. Multicard to Supply Secure IT Kits Under German Federal Governments Electronic ID Program
4. SCM Microsystems to Supply Readers for German Electronic ID Program
5. Chinese-German collaboration yields new species of Large Blue butterfly
6. Breema Center to Host International Intensive Week in Buhl, Germany
7. Wonder Auto Obtains a New World-class Customer in Germany
8. Terra Satellite sees Iceland volcanos ash moving into Germany
9. Germany starts its part in the International Cancer Genome Project
10. U of A and leading German researchers team up to build oil sands sustainability
11. Martin Hensen, head of e-strategies, UCB Germany: Making e-marketing more than just an add-on
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
German federal government bolsters neutron research in Garching
(Date:10/15/2014)... German Gauß-Allianz has admitted Johannes Gutenberg University Mainz ... Rhineland-Palatinate science hub continues to maintain a significant ... , "The acceptance of Johannes Gutenberg University ... is a milestone in the national and international ... The state of Rhineland-Palatinate can be proud that ...
(Date:10/15/2014)... SHELTON, Conn. , Oct. 15, 2014 NXT-ID, Inc. ... a biometric authentication company focused on the growing mobile commerce market ... NASDAQ MarketSite in Times Square on Monday October 13 th . ... with CTO David Tunnel and angel investor Mr. ... Gino Pereira , CEO of NXT-ID thanked his investors and employees ...
(Date:10/14/2014)... discriminating thieves, prostate cancer tumors scavenge and hoard copper ... such avarice may be a fatal weakness. , ... kill prostate cancer cells by delivering a trove of ... diseased cells brimming with the mineral, leaving non-cancer cells ... already commercially available for other uses, could soon be ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2
... exposure, serving size and parental behavior are the key drivers ... discussion at the 2013 Institute of Food Technologists (IFT) Annual ... standing-room only crowd of more than 200 conference attendees heard ... what their eating behaviors are and how the industry and ...
... approved to treat multiple sclerosis may also hold promise for ... that often leads to heart failure, researchers at the University ... findings are published in the July 16 issue of ... thickening of the heart muscle that shrinks the interior ...
... have taken part in an international study which has revealed ... in one of the most hostile environments on earth. ... Tibetan plateau, the largest high-altitude land mass in the world. ... genome which reveal how it copes with the extreme living ...
Cached Biology News:Taste rules for kids and healthy food choices 2MS drug shows promise for preventing heart failure 2Genetic secrets of the world's toughest little bird 2Genetic secrets of the world's toughest little bird 3
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Paris: FR0005175080) announces promising preliminary data from,the Phase ... an adjunct to first line chemotherapy in patients ... on-going trial is a randomized, open label and ... in combination with cisplatin and,gemcitabine compared to the ...
... BRIDGEWATER, New Jersey and BIRMINGHAM, Alabama,Jan. 10 ... a,leading international scientific and regulatory consulting firm with,specialized ... Food &,Nutrition, Chemicals and Agriculture, Biotech & Consumer ... the new name for their,Pharmaceutical & Healthcare Division., ...
... Essilor,of America, Essilor International,s US subsidiary, has strengthened ... the acquisition,of Interstate Optical Co., one of the ... Mansfield, Ohio and,Indianapolis, Indiana serve eye care professionals ... US$26 million and 210 employees., Present for ...
Cached Biology Technology:Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 2Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 3Cantox Announces the Launch of Ashuren Health Sciences Pharmaceutical Division 2
...
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Acetyl CoA Carboxylase Antibody...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Biology Products: